| Cellular Therapy to Obtain Spine Fusion |
Jul 2012 |
33 pages |
| Authors:
Elizabeth Davis; BAYLOR COLL OF MEDICINE HOUSTON TX
|
 | Surgery of the spine to fuse the vertebral bones is one of the most commonly performed operations with an estimated 350,000 Americans undergoing this surgery annually with estimated costs of $60 billion. Current procedures are highly invasive with limited success. The goal of this study is to develop a safe efficacious system for inducing spine fusion which will eliminate the need for invasive surgery. We have currently developed a cell ... |
|
| Multifunctional Virus-Nanoshell Assembly for Targeted Hyperthermia and Viral Gene Therapy for Breast Cancer |
Jun 2012 |
9 pages |
| Authors:
Fang Wei; RICE UNIV HOUSTON TX
|
| We aimed to develop a virus-Au NS assembly to specifically target breast cancer cells, and to use localized heat of NIR radiation of Au NS to destroy breast cancer cells in synergy with gene therapy. We proposed to develop virus-nanoshell assemblies by attaching adeno-associated virus (AAV) to gold nanoshells (Au NS) through chemical bonds. We have successfully completed majority of tasks 1 and 2 of our Statement of Work. Specifically, ... |
|
| T Cell Gene Therapy to Eradicate Disseminated Breast Cancers |
May 2012 |
52 pages |
| Authors:
Richard P Junghans; ROGER WILLIAMS MEDICAL CENTER PROVIDENCE RI
|
| There is no cure for metastatic breast cancer, which kills 40,000 American women (and 500 men) each year: all presently available treatments are palliative. Gene therapy techniques are used to introduce chimeric immunoglobulin-T cell receptors (IgTCR) into autologous patient T cells to create designer T cells that redirect the T cell immune system in a new type of immuno-gene therapy against breast cancer. Designer T cells have been created against ... |
|
| Safe Gene Therapy for Type 1 Diabetes |
Oct 2011 |
48 pages |
| Authors:
Massimo Trucco; PITTSBURGH UNIV PA
|
| Insulin expression was found in both lymph node (LN)-resident stromal cells of nonhemaetopoietic origin and bone marrow (BM)-derived antigen-presenting cells (APCs)1-3. Although little is known about the function of insulin expression in LNs, recent studies have shown that TSAexpressing stromal cells can effectively deplete TSA-specific autoreactive CD8+ T cells from the peripheral repertoire4-6. As for insulin expression in BM-derived APCs, discordant results have been reported regarding the specific cell subsets. ... |
|
| Development of a Nanotechnology Platform for Prostate Cancer Gene Therapy |
Jul 2011 |
20 pages |
| Authors:
Arash Hatefi; RUTGERS - THE STATE UNIV NEW BRUNSWICK NJ
|
| The objective of this research is to design and develop a nanocarrier that is able to evade the immune system, circulate in the blood stream, find its target prostate cancer cells, and transfer therapeutic genes into prostate cancer cells efficiently. The gene carrier is composed of: a) histone H2A peptide (H2A) to condense pDNA into nano-size particles (nanocarriers), b) a PC-3 specific targeting motif (TM) to target prostate cancer cells, ... |
|
| Induced Pluripotent Stem Cells as Potential Therapeutic Agents in NF1 |
MAY 2011 |
8 pages |
| Authors:
Jonathan Chernoff; INSTITUTE FOR CANCER RESEARCH PHILADELPHIA PA
|
| In this project, we are seeking to use induced pluripotent stem (iPS) cell technology as a potential therapy in neurofibromatosis 1 (NF1). In the first year, we have successfully produced iPS cells from fobroblasts from Nf1+/- mice and characterized the properties of these cells, which include growth in clusters, expression of stem cell markers, normal karyotype, and the ability to form teratomas in mice. We also have created a targeting ... |
|
| T-Cell Gene Therapy to Eradicate Disseminated Breast Cancers |
May 2011 |
103 pages |
| Authors:
Richard Junghans; ROGER WILLIAMS MEDICAL CENTER PROVIDENCE RI
|
| This Aim applies a randomization of 12 subjects to -IL2 or +IL2 arms at the maximum tolerated dose (MTD) or maximum practical dose (MPD) of designer T cells under a Phase Ib design. This will test the optimal biologic dose (OBD) in terms of the benefit of IL2 to T cell persistence and activity in vivo. There were three dose levels in the original Phase Ia: 109, 1010 and 1011 ... |
|
| T-Cell Gene Therapy to Eradicate Disseminated Breast Cancers |
May 2011 |
103 pages |
| Authors:
Richard Junghans; ROGER WILLIAMS MEDICAL CENTER PROVIDENCE RI
|
| This Aim applies a randomization of 12 subjects to IL2 or +IL2 arms at the maximum tolerated dose (MTD) or maximum practical dose (MPD) of designer T cells under a Phase Ib design. This will test the optimal biologic dose (OBD) in terms of the benefit of IL2 to T cell persistence and activity in vivo. There were three dose levels in the original Phase Ia: 109, 1010 and 1011 ... |
|
| The Role of the Co-Chaperone, CHIP, in Androgen-Independent Prostate Cancer |
FEB 2011 |
9 pages |
| Authors:
Courtney K. Phillips; MOUNT SINAI SCHOOL OF MEDICINE NEW YORK
|
| Androgen ablation, or androgen deprivation therapy (ADT), is the mainstay of treatment for patients with locally advanced or metastatic prostate cancer. This therapy is only temporizing, however, and within 3-4 years the vast majority of patients develop androgen independent prostate cancer (AIPC). Once a patient develops AIPC, treatment options are limited and less effective, with first line treatment providing only 13-15 month survival. This seminal event in disease progression has ... |
|
| Molecular Solutions to Low Vision Resulting from Battlefield Injuries |
Feb 2011 |
25 pages |
| Authors:
Darlene A Dartt; SCHEPENS EYE RESEARCH INST BOSTON MA
|
| We hypothesize that targeted molecular intervention can preserve vision threatened by battlefield trauma-induced corneal and retinal inflammation, corneal and retina/optic nerve apoptosis, ocular surface dry eye after refractive surgery, and retinal degeneration. We are studying the consequences of trauma-induced (1) corneal inflammation using a gene therapy approach of providing soluble Fas ligand to the cornea to determine if this ligand can suppress corneal inflammation in mice; (2) retinal inflammation by ... |
|
| Prostate Cancer Evaluation: Design, Synthesis and Evaluation of Novel Enzyme-Activated Proton MRI Contrast Agents |
OCT 2010 |
31 pages |
| Authors:
Jian-Xin Yu; TEXAS UNIV SOUTHWESTERN MEDICAL SCHOOL AT DALLAS
|
| The lacZ gene encoding E. coli beta-gal has already been recognized as the most commonly used reporter system in cancer gene therapy. Moreover, prostate-specific membrane antigen (PSMA) has been identified as an ideal antigenic target in prostate cancer. We propose to develop a novel class of Gd(III)-based MRI contrast agents for in vivo detection of beta-gal or PSMA activity. This new concept of the Gd(III)-based MRI contrast agents is composed ... |
|
| Novel Targeting Approach for Breast Cancer Gene Therapy |
SEP 2010 |
14 pages |
| Authors:
Srinath Palakurthi; TEXAS A AND M UNIV COLLEGE STATION HEALTH SCIENCE CENTER
|
| Impaired balance between pro-apoptotic and anti-apoptotic molecules is common in cancer cells, including breast cancer, and it plays an important role in tumor initiation and progression. Proapoptotic gene therapy aims at enhancing the capacity of tumor cells to undergo apoptosis and renders the tumors sensitive to classical anticancer drugs and radiotherapy. We developed a novel therapeutic strategy that combines both targeted gene (p53) delivery using sigma-receptor ligand-conjugated PAMAM dendrimers, followed ... |
|
| Biotechnology: Genetically Engineered Pathogens (The Counterproliferation Papers, Future Warfare Series No. 53) |
Jun 2010 |
42 pages |
| Authors:
Joel O Almosara; USAF COUNTERPROLIFERATION CENTER MAXWELL AFB AL
|
| The bright side of advancements in biotechnology is offering great promise in improving human health, combating diseases, and promoting a better quality of life. But, for every bright side there is an opposing dark side. Biotechnology, when used maliciously or negligently, can destroy human life. Advanced biotechnology, in particular genetically engineered pathogens such as viruses, and bacteria, could become a potential choice for use as biological warfare agents. Will advancements ... |
|
| Molecular Solutions to Low Vision Resulting from Battlefield Injuries. Addendum |
May-2009 |
12 pages |
| Authors:
Darlene A Dartt; SCHEPENS EYE RESEARCH INST BOSTON MA
|
| We hypothesize that targeted molecular intervention can preserve vision threatened by battlefield trauma-induced corneal and retinal inflammation, corneal and retina/optic nerve apoptosis, ocular surface dry eye after refractive surgery, and retinal degeneration. We are studying the consequences of trauma-induced (1) corneal inflammation using a gene therapy approach of providing soluble Fas ligand to the cornea to determine if this ligand can suppress corneal inflammation in mice; (2) retinal inflammation by ... |
|
| Prostate Cancer Evaluation: Design, Synthesis and Evaluation of Novel Enzyme-Activated Proton MRI Contrast Agents |
Oct-2008 |
22 pages |
| Authors:
Jian-Xin Yu; TEXAS UNIV SOUTHWESTERN MEDICAL SCHOOL AT DALLAS
|
| The lacZ gene encoding E. coli beta-gal has already been recognized as the most commonly used reporter system in cancer gene therapy. Moreover, prostate-specific membrane antigen (PSMA) has been identified as an ideal antigenic target in prostate cancer. We propose to develop a novel class of Gd(III)-based MRI contrast agents for in vivo detection of beta-gal or PSMA activity. This new concept of the Gd(III)-based MRI contrast agents is composed ... |
|
| Design of an NF-kB Activation-Coupled Apoptotic Molecule for Prostate Cancer Therapy |
31-Jul-2008 |
23 pages |
| Authors:
Wannian Yang; GEISINGER CLINIC DANVILLE PA
|
| This proposal is to establish an effective and selective gene therapy technique for prostate cancer. The main idea is to create an NF-kB/Caspase-3 fusion protein, designated as NF-kB activation-coupled apoptotic molecule (NACAM), that couples activation of NF-kB to activation of Caspase-3, thus to apoptosis. During the eighteen months, we constructed 32 plasmids for testing the function of NACAM and determined the expression of the plasmids in HEK293 cells. We further ... |
|
| Gene Therapy for Osteolytic Breast Cancer Bone Metastasis |
Jun-2008 |
8 pages |
| Authors:
Selvarangan Ponnazhagan; ALABAMA UNIV IN BIRMINGHAM
|
| Bone is the frequent metastatic site for human breast cancer resulting in significant morbidity and mortality in patients with advanced disease. Osteoprotegerin (OPG) is a decoy receptor that competes with RANK for RANKL, thus, modulating the effects of RANKL. However, during the metastatic events involving cancer and stromal cell interaction, endogenous OPG levels are markedly reduced. Thus, OPG remains an effective molecule for future therapies for bone metastasis. We sought ... |
|
| Molecular Solutions to Low Injuries Resulting from Battlefield Injuries. Addendum |
01-May-2008 |
19 pages |
| Authors:
Darlene A Dartt; SCHEPENS EYE RESEARCH INST BOSTON MA
|
| We hypothesize that targeted molecular intervention can preserve vision threatened by battlefield trauma-induced corneal and retinal inflammation, corneal and retina/optic nerve apoptosis, ocular surface dry eye after refractive surgery, and retinal degeneration. We are studying the consequences of trauma-induced (1) corneal inflammation using a gene therapy approach of providing soluble Fas ligand to the cornea to determine if this ligand can suppress corneal inflammation in mice; (2) retinal inflammation by ... |
|
| Systemic and Gene Modified Mesenchymal Stem Cell Therapy for Metastatic Prostate Cancer |
01-May-2008 |
7 pages |
| Authors:
Selvarangan Ponnazhagan; ALABAMA UNIV IN BIRMINGHAM
|
| Bone is the frequent metastatic site for human prostate cancer resulting in significant morbidity and mortality in patients with advanced disease. The type of bone defect encountered in prostate cancer bone metastasis is osteoblast lesions resulting in excess bone. However, initiation of osteoclastogenesis is first aided by osteolysis, mediated by osteoclasts. The areas provided as source for osteoblast accumulation later leads to thickening of the bone. In this proposal, we ... |
|
| Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cell |
01-Apr-2008 |
11 pages |
| Authors:
Yan Cui; LOUISIANA STATE UNIV NEW ORLEANS
|
| Prostate cancer is the second leading cause of cancer death among men in North America. Our long-range goal is to develop an innovative non-invasive approach to reach those metastatic prostate cancer cells via tumor interacting stroma cells and eliminate them on-site through cytotoxic gene delivery. This is achieved by using engineered mesenchymal stem cells (MSC) as a gene delivery vehicle to reach tumor cells as they tend to serve as ... |
|
| A Targeted Mulifunctional Platform for Imaging and Treatment of Breast Cancer and Its Metastases Based on Adenoviral Vectors and Magnetic Nanoparticles |
FEB 2008 |
50 pages |
| Authors:
Maaike Everts; ALABAMA UNIV IN BIRMINGHAM
|
| Nanotechnology holds many promises for the imaging and treatment of breast cancer. In particular, magnetic nanoparticles can be utilized for tumor imaging via magnetic resonance imaging (MRI) techniques and tumor treatment by heating after exposure to an alternating magnetic field. However, selective targeting of the nanoparticles to the tumor cells needs to be accomplished before the imaging or therapy can be successful. In this respect, adenoviral (Ad) vectors for gene ... |
|
| Development of a Gene Therapy Trial for Metastatic Prostate Cancer |
01-Jan-2008 |
37 pages |
| Authors:
Thomas A Gardner; INDIANA UNIV AT BLOOMINGTON
|
| This award was to support the infrastructure and development of a Phase I clinical trial for men with metastatic prostate cancer. The Phase I trial under development employs a prostate restricted replicative adenovirus (PRRA) with excellent preclinical performance in vitro and in vivo in relevant animal models of human prostate cancer. Several components of the statement of work for this award have been completed. The key component of this trial ... |
|
| Identification of a Protein for Prostate-Specific Infection |
Dec-2007 |
7 pages |
| Authors:
Shen Pang; CALIFORNIA STATE UNIV LOS ANGELES
|
| In this proposal, we will identify and clone a protein that can be used to generate infection-specific gene therapy vector. We expect that using this protein to modify various gene therapy vectors, we can specifically deliver cytotoxic genes into prostate cancer cells using systemic treatment, and eventually eradicate metastatic prostate cancer cells in patients. In summary, although we worked very hard to perform the studies we proposed, we failed to ... |
|
| Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer |
Dec-2007 |
73 pages |
| Authors:
James M Mathis; LOUISIANA STATE UNIV IN SHREVEPORT
|
| Adenovirus (Ad)-mediated transduction of dendritic cells (DCs) is inefficient because of the lack of the primary Ad receptor, CAR. CD40 is a surface marker expressed by DCs that plays a crucial role in their maturation and subsequent stimulation of T cells. DC infection with Ad targeted to the CD40 results in increased gene transfer. Cells transduced with CD40-targeted Ad5-SV40-TAg vector showed increased expression of transgene and expression of co-stimulatory molecules ... |
|
| A Double Selection Approach to Achieve Specific Expression of Toxin Genes for Ovarian Cancer Gene Therapy |
01-Nov-2007 |
351 pages |
| Authors:
David T Curiel; Gene Siegal; Minghui Wang; ALABAMA UNIV IN BIRMINGHAM
|
| Gene therapy is a novel treatment modality which offers great potential for the control of carcinoma of the ovary. The efficacy of such approaches, however, is currently limited due to the inability of available gene delivery vehicles (vectors) to achieve efficient and selective gene transfer to target tumor cells. Proposed herein is a strategy to modify one candidate vector, recombinant adenovirus, such that it embodies the requisite properties of efficacy ... |
|
| Prostate Cancer Evaluation: Design, Synthesis, and Evaluation of Novel Enzyme-Activated Proton MRI Contrast Agents |
OCT 2007 |
22 pages |
| Authors:
Jian-Xin Yu; TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
|
| The lacZ gene encoding E. coli beta-gal has already been recognized as the most commonly used reporter system in cancer gene therapy. Moreover, prostrate-specific membrane antigen (PSMA) has been identified as an ideal antigenic target in prostate cancer. We propose to develop a novel class of Gd(III)-based MRI contrast agents for in vivo detection of beta-gal or PSMA activity. This new concept of the GD(III)-based MRI contrast agents is composed ... |
|
| A Targeted Multifunctional Platform for Imaging and Treatment of Breast Cancer and Its Metastases Based on Adenoviral Vectors and Magnetic Nanoparticles |
AUG 2007 |
53 pages |
| Authors:
Maaike Everts; Vaibhav Saini; ALABAMA UNIV IN BIRMINGHAM
|
| Nanotechnology holds many promises for the imaging and treatment of breast cancer. In particular, magnetic nanoparticles can be utilized for tumor imaging via magnetic resonance imaging (MRI) techniques and tumor treatment by heating after exposure to an alternating magnetic field. However, selective targeting of the nanoparticles to the tumor cells needs to be accomplished before the imaging or therapy can be successful. In this respect, adenoviral (Ad) vectors for gene ... |
|
| Therapeutic Conversion of Viability Promoting MCL1 to Death-Inducing Forms: A Novel Strategy for Breast Cancer |
01 JUL 2007 |
12 pages |
| Authors:
Ruth W. Craig; DARTMOUTH COLL HANOVER NH
|
| The BCL2 family member MCL1 is expressed in breast cancer cells in its full-length, anti-apoptotic form. The goal of this project was to induce conversion of MCL1 to pro-apoptotic forms as a means of enhancing the death of these cells. The approach was identify means of inducing alternate splicing of MCL1 using antisense oligonucleotides, since splice variants are known to promote cell death rather than cell survival. We identified reagents ... |
|
| Molecular Solutions to Low Injuries Resulting from Battlefield Injuries |
01 MAY 2007 |
17 pages |
| Authors:
Darlene A. Dartt; SCHEPENS EYE RESEARCH INST BOSTON MA
|
| We hypothesize that targeted molecular intervention can preserve vision threatened by battlefield trauma-induced corneal and retinal inflammation, corneal and retina/optic nerve apoptosis, ocular surface dry eye after refractive surgery, and retinal degeneration. We are studying the consequences of trauma-induced (1) corneal inflammation using a gene therapy approach of providing soluble Fas ligand to the cornea to determine if this ligand can suppress corneal inflammation in mice; (2) retinal inflammation by ... |
|
| Systemic and Gene Modified Mesenchymal Stem Cell Therapy for Metastatic Prostate Cancer |
MAY 2007 |
7 pages |
| Authors:
Selvarangan Ponnazhagan; ALABAMA UNIV IN BIRMINGHAM
|
| Bone is the frequent metastatic site for human prostate cancer resulting in significant morbidity and mortality in patients with advanced disease. The type of bone defect encountered in prostate cancer bone metastasis is osteoblast lesions resulting in excess bone. However, initiation of osteoclastogenesis is first aided by osteolysis, mediated by osteoclasts. The areas provided as source for osteoblast accumulation later leads to thickening of the bone. In this proposal, we ... |
|
| Angiogenesis and Therapeutic Approaches to NF1 Tumors |
APR 2007 |
58 pages |
| Authors:
David F. Muir; FLORIDA UNIV GAINESVILLE
|
| The goal of this project is to specify how anti-angiogenic approaches can be effectively applied to NF1 tumors. Invivo and in vitro models were used to firmly conclude that Nf1 haploinsufficiency in endothelial cells results inexaggerated proliferation and angiogenesis in response to key pro-angiogenic factors. Results implicate these growthfactor pathways as potential targets for therapeutic agents. In addition, endostatin was found to be a potent inhibitorof Nf1+/- endothelial cell migration ... |
|
| Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs |
MAR 2007 |
30 pages |
| Authors:
Li Liu; TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
|
| Gene therapy shows promise for treating prostate cancer and is being exploited in several clinical trials. A major hurdle is establishing a method of verifying transgene activity in situ. Beta-galactosidase (beta-gal) was historically the most popular reporter gene for molecular biology. I have introduced a novel concept for further exploration of gene therapy using beta- galactosidase to activate a broad-spectrum chemotherapeutic to assess the efficacy of the pro-drugs in vitro ... |
|
| Nuclear Imaging for Assessment of Prostate Cancer Gene Therapy |
MAR 2007 |
14 pages |
| Authors:
Dongfeng Pan; VIRGINIA UNIV CHARLOTTESVILLE
|
| Background: Combination of the cytotoxic viral thymidine kinase (tk) and the prodrug acyclovir (ACV) has been reported to inhibit the growth of the C4-2 tumor a subline of LNCaP. However it remains unsolved to non-invasively detect the in vivo distribution expression and persistence of the toxic gene as well as to evaluate the therapeutic effect. In this project we will develop a nuclear gene imaging approach to assist the cytotoxic ... |
|
| FGFR4 Downregulation of Cell Adhesion in Prostate Cancer |
MAR 2007 |
6 pages |
| Authors:
Daniel J. Donoghue; April N. Meyer; Kristine A. Drafahl; CALIFORNIA UNIV SAN DIEGO LA JOLLA
|
| We have made excellent progress in the preliminary stages of our project to examine the role of FGFR4 G388R in altering cell adhesion in prostate cancer. This includes acquiring expertise in the passage and transfection for gene expression studies using prostate cancer cell lines. A key accomplishment is the demonstration of feasibility of ponasterone; A inducibility of FGFR4 expression in PC3 cells. We hope to successfully create these inducible cells ... |
|
| Molecular Engineering of Vector-Based Oncolytic and Imaging Approaches for Advanced Prostate Cancer |
01-Feb-2007 |
57 pages |
| Authors:
Lily Wu; CALIFORNIA UNIV LOS ANGELES
|
| Hormone refractory and metastatic prostate cancer are not well understood. Better animal models, diagnostic and treatment modalities are sorely needed for these advanced stages of disease. We have developed metastatic prostate cancer animal models that can be monitored by molecular imaging. To target metastatic disease, we have incorporated a highly potent and prostate-specific transcriptional regulatory system (TSTA) in adenoviral vectors such that the expression of imaging reporter gene and therapeutic ... |
|
| Vasculature-Specific Adenovirus Vectors for Gene Therapy of Prostate Cancer |
FEB 2007 |
9 pages |
| Authors:
Victor Krasnykh; M D ANDERSON CANCER CENTER HOUSTON TX
|
| In Year 3 of the project we have completed Task 3 and began the work in Task 4 (as per approved Statement of Work). As a result, we have rescued, propagated and characterized a panel of adenovirus vectors that are now ready for the in vivo studies that will conclude the project. To facilitate the monitoring of tumor growth and regression in these studies, we have also developed cell lines ... |
|
| Formulated Delivery of Enzyme/Prodrug and Cytokine Gene Therapy to Promote Immune Reduction of Treated and Remote Tumors in Mouse Models of Prostate Cancer |
JAN 2007 |
127 pages |
| Authors:
Pamela J. Russell; Aparajita Khatri; Yasmin Husaini; Jane Chapman; NEW SOUTH WALES UNIV SYDNEY (AUSTRALIA)
|
| Prostate cancer is the second highest cause of cancer death in men in Western society. Early disease is treatable by surgery or radiation but once late stage disease becomes refractory to hormone removal patient care is limited to pain management. New treatments are needed. We use gene therapy alone and in combination with hormones called cytokines that stimulate the immune system. The concept is that delivering a cell-killing agent to ... |
|
| Control of DNA Dehybridization via Nanoparticle Antennas for Antisense Gene Therapy |
2007 |
|
| Authors:
Kimberly Hamad-Schifferli; MASSACHUSETTS INST OF TECH CAMBRIDGE
|
 | The goal of this proposal is to develop the use of a nanoscale interface to protein translation machinery to control translation. External magnetic fields excite the nanoscale interface and thus switch on translation of a protein. This technique would enable time-specific control of protein expression, and would enable new techniques in disease diagnosis and therapy. These objectives are in line with the original proposal. |
|
| Identification of a Protein for Prostate-Specific Infection |
DEC 2006 |
6 pages |
| Authors:
Shen Pang; CALIFORNIA UNIV LOS ANGELES
|
| In this proposal, we will identify and clone a protein that can be used to generate infection-specific gene therapy vector. We expect that using this protein to modify various gene therapy vectors, we can specifically deliver cytotoxic genes into prostate cancer cells using systemic treatment, and eventually eradicate metastatic prostate cancer cells in patients. During the third year, we inserted the sequences that encode these two peptides to modify lentiviral ... |
|
| Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer |
DEC 2006 |
17 pages |
| Authors:
James M. Mathis; LOUISIANA STATE UNIV IN SHREVEPORT HEALTH SCIENCE CENTER
|
| Adenovirus (Ad)-mediated transduction of dendritic cells (DCs) is inefficient because of the lack of the primary Ad receptor CAR. CD40 is a surface marker expressed by DCs that plays a crucial role in their maturation and subsequent stimulation of T cells. DC infection with Ad targeted to the CD40 results in increased gene transfer. Cells transduced with CD40-targeted Ad5-SV40-TAg vector showed increased expression of transgene and expression of co-stimulatory molecules ... |
|
| Prostate Cancer Evaluation: Design, Synthesis, and Evaluation of Novel Enzyme-Activated Proton MRI Contrast Agents |
01 OCT 2006 |
14 pages |
| Authors:
Jian-Xin Yu; TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
|
| The lacZ gene encoding E. coli beta-gal has already been recognized as the most commonly used reporter system in cancer gene therapy. Moreover, prostrate-specific membrane antigen (PSMA) has been identified as an ideal antigenic target in prostate cancer. We propose to develop a novel class of Gd(III)-based MRI contrast agents for in vivo detection of beta-gal or PSMA activity. This new concept of the GD(III)-based MRI contrast agents is composed ... |
|
| Mechanisms Down-Regulating Sprouty1, a Growth Inhibitor in Prostate Cancer |
OCT 2006 |
62 pages |
| Authors:
Bernard Kwabi-Addo; BAYLOR COLL OF MEDICINE HOUSTON TX
|
| The Sprouty gene family negatively regulates growth factor-induced receptor tyrosine kinase signaling with a potential tumor suppressor function in cancer. I have demonstrated that Sprouty1 is down-regulated in human prostate cancer (PCa). The purpose of the present study is to characterize the molecular mechanisms regulating Sprouty1 expression in the human PCa. Results. I have carried out deletion analysis coupled with reporter gene assays to characterize Sprouty1 promoter activity. Electrophoretic mobility ... |
|
| Vectors for Treatment of Metastatic Breast Cancer |
AUG 2006 |
56 pages |
| Authors:
Albert B. Deisseroth; SIDNEY KIMMEL CANCER CENTER SAN DIEGO CA
|
| The objective is to design, build and study vectors which would be able to break tolerance to breast cancer associated TAA and to be used to suppress the recurrence of metastatic breast cancer following surgical resection. The hypothesis is that by fusing the CD40 ligand stripped of its transmembrane domain and intracytoplasmic domains, to a breast cancer TAA such as the extracellular domain of the her-2-neu receptor, or the extracellular ... |
|
| Anti-Androgen Receptor RNA Enzyme as a Novel Therapeutic Agent for Prostate Cancer In Vivo |
AUG 2006 |
15 pages |
| Authors:
Shuo Chen; TEXAS UNIV HEALTH SCIENCE CENTER AT SAN ANTONIO
|
| Prostate cancer is the second leading cause of cancer death among men in the western world. Androgen plays a crucial role in the development and growth of normal prostate gland and prostate cancer. Action of androgen is mediated by an androgen receptor (AR) and the AR exerts androgen-regulated gene expression. Standard therapy relies on androgen ablation to remove or block the action of androgens. This therapy results in a regression ... |
|
| Multifunctional Magnetic Nanowires for Biomagnetic Interfacing Concepts |
14 JUL 2006 |
27 pages |
| Authors:
D. H. Reich; C. S. Chen; C. L. Chien; G. J. Meyer; K. Leong; P. C. Searson; G. Xiao; JOHNS HOPKINS UNIV BALTIMORE MD
|
| A technique of increasing importance in biotechnology is the manipulation of cells and biomolecules with small magnetic particles. In this research program, we developed a new type of carrier particle, multifunctional magnetic nanowires, which possess tunable magnetic and chemical properties. These nanowires can carry out multiple tasks e.g. binding multiple types of molecules, probing chemical activity in specific regions of a cell, and responding to light as well as to ... |
|
| Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells |
APR 2006 |
6 pages |
| Authors:
Yan Cui; LOUISIANA STATE UNIV NEW ORLEANS
|
| Prostate cancer is the second leading cause of cancer death among men in North America mostly due to a high incidence of cancer cell spreading to bones (metastasis) which is incurable by any currently used regimens. Our long-range goal is to develop an innovative non-invasive approach to reach those metastatic prostate cancer cells via tumor interacting stromal cells and eliminate them on-site through cytotoxic gene delivery. This will be achieved ... |
|
| Angiogenesis and Therapeutic Approaches to NF1 Tumors |
APR 2006 |
61 pages |
| Authors:
David F. Muir; FLORIDA UNIV GAINESVILLE
|
| The main goal of this project is to specify how anti-angiogenic approaches can be effectively applied to NF1 tumors. To this end, we will first determine whether NF1 heterozygosity alters the responsiveness of endothelial cells to angiogenic regulators. We will test if Nf1-/+ endothelial cells are particularly responsive to pro-angiogenic factors produced by NF1 tumor cells and, perhaps even more importantly, which anti-angiogenic factors are most effective in abrogating the ... |
|
| Functional Geno,ic Analysis of Breast Cancer Cell Tumorigenicity Using a Noval Gene Silencing Resource |
APR 2006 |
16 pages |
| Authors:
Douglas S. Conklin; STATE UNIV OF NEW YORK AT ALBANY RESEARCH FOUNDATION
|
| The year 1 aims were primarily concerned with collecting shRNA constructs so that a small number that have inhibitory effects on breast cancer progression in vivo models could be identified. We have collated a set of encoded hairpins targeting genes overexpressed in ErbB-2 positive breast tumors. We have also spent considerable effort testing the compatibility of several assays for cellular correlates of tumorigenicity with high throughput gene transfer. To date ... |
|
| Cell Therapy to Obtain Spinal Fusion |
FEB 2006 |
29 pages |
| Authors:
Elizabeth A. Olmstead-Davis; BAYLOR COLL OF MEDICINE HOUSTON TX
|
| Surgery of the spine to fuse the vertebral bones is one of the most commonly performed operations with an estimated 400,000 Americans to undergo this surgery in the year 2003. It is useful for the treatment of scoliosis, instability and painful degenerative conditions of the spine, but as currently performed is highly invasive and has a low success rate. Often bone must be surgically removed from the pelvis, to implant ... |
|
| Formulated Delivery of Enzyme/Prodrug and Cytokine Gene Therapy to Promote Immune Reduction of Treated and Remote Tumors in Mouse Models of Prostate Cancer |
JAN 2006 |
99 pages |
| Authors:
Pamela J. Russell; Aparajita Khatri; Yasmin Husaini; Jane Chapman; NEW SOUTH WALES UNIV SYDNEY (AUSTRALIA)
|
| Prostate cancer is the second highest cause of cancer death in men in Western society. Early disease is treatable by surgery or radiation, but once late stage disease becomes refractory to hormone removal, patient care is limited to pain management. New treatments are needed. We use gene therapy, alone and in combination with hormones called cytokines that stimulate the immune system. The concept is that delivering a cell-killing agent to ... |
|
Reports by Keyword(s)
GENE THERAPY
